retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Reports Obesity drug research, triple G

Yale Medicine experts explain who qualifies, who can prescribe, and what to expect.

Evidence-based comparison of retatrutide (GIP/GLP-1/glucagon triple agonist) and survodutide (GLP-1/glucagon dual agonist) for weight loss, MASH, and metabolic disease based on Phase 2 clinical trial data.

Recently, multiple case reports and studies indicating safety risks for these medications and their use in patients planning to undergo general anesthesia have been published, as retained gastric contents can lead to intraoperative aspiration

Stool softeners don't address the root cause

Eli Lillys first nine months of 2025 underscored the scale of the GLP-1 surge: Mounjaro and Zepbound generated $39.5 billion in revenue and surpasses Mercks Keytruda as the worlds best-selling medicine[5]

Official supply shortages persisted for most of 2024, as surging demand for AOMs continued to outstrip product supply, despite limited reimbursement, which presented an opportunity quickly seized upon by U.S